Search

Now showing items 11-20 of 137

Fingolimod modulates microglial activation to augment markers of remyelination

Jackson, SJ; Giovannoni, G; Baker, D (2011-07-05)

No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine.

Pakpoor, J; Disanto, G; Altmann, DR; Pavitt, S; Turner, BP; Marta, M; Juliusson, G; Baker, D; Chataway, J; Schmierer, K (2015-12)

OBJECTIVE: To compare the cancer risk of cladribine and other disease-modifying drugs (DMDs) in trials of people with relapsing multiple sclerosis (pwRMS). METHODS: Meta-analysis of phase III trials of licensed DMDs for ...

Disposable MMP-9 sensor based on the degradation of peptide cross-linked hydrogel films using electrochemical impedance spectroscopy.

Biela, A; Watkinson, M; Meier, UC; Baker, D; Giovannoni, G; Becer, CR; Krause, S (2015-01-28)

Matrix metalloproteinase-9 (MMP-9) plays an important role in both physiological and pathological processes. This enzyme is a peripheral biomarker of neuroinflammation in multiple sclerosis (MS), a chronic autoimmune disease ...

Characterization of immune response to neurofilament light in experimental autoimmune encephalomyelitis

Puentes, F; van der Star, BJ; Victor, M; Kipp, M; Beyer, C; Peferoen-Baert, R; Ummenthum, K; Pryce, G; Gerritsen, W; Huizinga, R;... (2013)

Autoimmunity to neuronal proteins occurs in several neurological syndromes, where cellular and humoral responses are directed to surface as well as intracellular antigens. Similar to myelin autoimmunity, pathogenic immune ...

Pentraxin-3 is upregulated in the central nervous system during MS and EAE, but does not modulate experimental neurological disease

Ummenthum, K; Peferoen, LAN; Finardi, A; Baker, D; Pryce, G; Mantovani, A; Bsibsi, M; Bottazzi, B; Peferoen-Baert, R; van der Valk, P;... (2016-03)

Depletion of CD52-positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune-tolerance promoting CD8 T-cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis

von Kutzleben, S; Pryce, G; Giovannoni, G; Baker, D (2017-04)

Characterisation of Transcriptional Changes in the Spinal Cord of the Progressive Experimental Autoimmune Encephalomyelitis Biozzi ABH Mouse Model by RNA Sequencing

Sevastou, I; Pryce, G; Baker, D; Selwood, DL (2016-06-29)

Ageing and recurrent episodes of neuroinflammation promote progressive experimental autoimmune encephalomyelitis in Biozzi ABH mice

Peferoen, LAN; Breur, M; van de Berg, S; Peferoen-Baert, R; Boddeke, EHWGM; van der Valk, P; Pryce, G; van Noort, JM; Baker, D; Amor, S (2016-10)

Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis

Baker, D; Marta, M; Pryce, G; Giovannoni, G; Schmierer, K (2017-02)

The problem with repurposing: Is there really an alternative to Big Pharma for developing new drugs for multiple sclerosis?

Giovannoni, G; Baker, D; Schmierer, K (2015-01-01)

©2014 Elsevier B.V. All rights reserved. If it is not feasible to develop licensed drugs to the stage that they can actually be prescribed for a new indication, can we justify, either ethically or economically, the undertaking ...

1
2
3
4
5
. . .
14